According to American College of Cardiology, a survey of 77 comprehensive Care Centres for pulmonary hypertension (PH), the patient rate of infection with covid-19 Was 2.1 cases per 1000 patients and associated mortality rate happened to be 12%. Although covid-19 was not too prevalent among PH patients, the death rate did appear to be higher among the infected.
According to the latest article by Scientific Reports, “covid-19 patients with hypertension are at potential risk of worsened organ injury”. The data analysed shows there were 28.2% covid-19 patients with hypertension which calculates it to be the most common chronic illness followed by diabetes and cardiovascular disease. United Therapeutics in December 2020 received FDA approval for Remodulin used as an implantable system for patients with WHO Group 1 Pulmonary arterial hypertension, developed by the collaboration between United Therapeutics and Medtronic. Patients on the Remodulin implantable pump need to refill the pump every 3-4 months by health care professionals.
In January 2020, Medtronic (Ireland) launched Efficio, a cloud based data management software to be used with SychroMed II intrathecal drug delivery system. It helps in efficiently managing the drug delivery pumps to treat patients suffering from chronic pain, cancer and severe diseases.
In August 2020, Baxter International received CE mark for its Evo IQ Syringe Infusion system from Australia’s Therapeutic Goods Administration for Evo IQ Syringe Infusion System. The system has been developed to optimize efficiency for clinicians for enhancing flexibility to help patients. With the approval, Baxter is expected to strengthen its medication delivery segment.
In 2019 also manufacturers focussed on collaborations. For example:
Braun Medical Inc collaborated with STANLEY Health care for integrating the health care enterprise standards. The collaboration includes improvement in patient safety, optimize asset utilization, and increase staff efficiency. The infusion management software communicates with MobileView software platform to provide real-time pump status data.
Pulmonary hypertension is a rapidly growing issue, especially among elderly population and in countries with the rise in aging population. The increasing pervasiveness of Pulmonary Arterial Hypertension (PAH) and a growing number of cases globally are driving demand for implantable pump catheter facilitating catheter implantation during treatment of PAH.
Researchers have also found Methamphetamine abuse leading to PAH. The US accounts for the maximum number of methamphetamine-related PAH patients. A significant drop in the blood stream infection is driving the demand for implantable pump catheter in PAH treatment.
Development and Testing of Several New Classes of Drugs for PAH
New drugs with vasodilator potential and other benefits including anti-smooth muscle proliferation, platelet inhibition, and improved cardiac function are being developed. Scientists at Stanley Manne Children’s Research Institute have identified a drug that inhibits HIF-2a gene. The drug targets mechanism behind PAH development. Researchers are planning to launch a clinical trial in 2019.
Along with ongoing drug formulation efforts for PAH-affected patients, recent approval by FDA for an implantable system for Remodulin, reducing the risk of complications including infection in PAH patients.
Precision Medicine Approach in Pulmonary Arterial Hypertension
Clinical outcomes and responses to PAH therapy are being modified by multiple factors, including genetic variations that are different for each person. Some recent studies have found that distinct molecular and genetic pathways in vasolidator responsive patients than non-vasoresponsive pulmonary arterial hypertension, this supports the use of the molecular technique in predicting drug responsiveness.
The treatment with calcium channel blockers is being considered a form of personalized medicine, as it is very effective in a small number of patients. Since this, no big discovery has been made in the personalized treatment of PAH. Pulmonary Arterial Hypertension behaves differently in every patient, this is driving the need for a personalized approach. The PVDOMICS initiative launched by NHLBI division aims to facilitate better treatment for PAH along with the precision medicines. Meanwhile, genetics coupled with deep molecular phenotyping is offering chances for new drug targets for PAH and possibility for more personalized medicines.
Possible System Complications can lead to Side-Effects
System complication in implantable pump catheter include tissue damage and might also lead to the damage of underlying system. The implantable pump catheter can also tear, leak or disconnect, resulting in the transfer of medication in other areas under the skin where the pump is fixed.
The risk associated with implantable pump catheter includes various symptoms of overdose and symptoms of early withdrawal. Failure of Implantable pump catheter may lead to underdose, overdose, and withdrawal which can be life-threatening. After finding that patients are being treated with medications not approved for use with implanted pumps, FDA alerted patients and healthcare providers about complications of using unapproved medications with implanted pumps.
The US Food and Drug Administration (FDA) has approved Medtronic’s Implantable System for Remodulin. Remodulin is a drug developed by United Therapeutics that helps in treating pulmonary arterial hypertension. The recently approved system allows the whole thing to be implanted and administration of doses automatically via IV catheter.
FDA has also approved Medtronic’s new SynchroMed(TM)II myPTM(TM) Personal Therapy Manager for patients to manage chronic pain. myPTM is an app on a Samsung J3 smart device that is customized for patients to manage chronic pain.
North America is expected to hold a strong position in the implantable pump catheter market followed by Europe. US is likely to witness robust growth in the market due to the presence of well-established medical device companies, generating a majority of its sales from the US healthcare system. Japan is also expected to see healthy growth in the coming years owing to the rise in government spending on healthcare.
Based on the end-user, the market is segmented into,
- Ambulatory Surgical Centers
Fact.MR offers custom research services that help clients to get specific research solutions
We are committed towards customer satisfaction and quality service.